S&P/ASX 200 Index (ASX: XJO) shares are down 1% to 8,757 points on Tuesday.
Let's take a look at some new ratings from the experts this week (courtesy The Bull).
Ramelius Resources Ltd (ASX: RMS)
The Ramelius Resources share price is $3.54, down 2.4% today and down 9% over 12 months.
Michael Gable from Fairmont Equities has a buy rating on this ASX 200 gold mining share.
Gable said:
Gold prices appear to have bottomed after trading much higher in early 2026.
The share prices of various gold mining stocks have held up well, and this sign of strength is bullish.
I'm expecting gold mining stock prices to rally higher from here as they follow potentially higher gold prices.
RMS is an Australian gold producer with no debt and strong free cash flow.
It pays a fully franked dividend and has been buying back shares.
RMS is highly leveraged to an increasing gold price and the company's outlook is bright.
Medibank Private Ltd (ASX: MPL)
The Medibank Private share price is $4.73, down 0.4% today and up 1% over 12 months.
Andrew Wielandt from DP Wealth Advisory has a hold rating on this ASX 200 financial share.
Wielandt said:
Medibank remains one of Australia's highest quality defensive businesses. The company benefits from a dominant position in private health insurance, recurring premium income and a strong balance sheet.
Population growth and an ageing demographic continue to provide long term support for the sector.
However, MPL now trades on a premium valuation relative to many other defensive businesses.
While the company remains well positioned, much of the good news is factored into the share price, leaving MPL a hold.
Washington H. Soul Pattinson and Co Ltd (ASX: SOL)
Washington H. Soul Pattinson and Co shares are $45.93, down 0.7% today and up 22% over 12 months.
Toby Grimm from Baker Young has a sell rating on Soul Patts shares.
Grimm said:
SOL merged with Brickworks in September 2025, a move that was strategically and financially beneficial, as shown by its strong net asset value and earnings and dividend growth in full year 2026.
SOL has a historic track record of solid returns, but we struggle to justify a recent premium without ascribing strong upside expectations for SOL's unlisted investments.
SOL has significant exposure to private credit and data centre development, which has experienced diminishing market sentiment in recent months.
Following merger benefits and a stock trading above our $38.50 valuation, investors can consider taking profits at current levels.
The post Buy, hold, sell: Ramelius Resources, Medibank, Soul Patts shares appeared first on The Motley Fool Australia.
Fetching Disclosure...
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026